JPMorgan analyst Chris Schott raised the firm’s price target on Teva (TEVA) to $35 from $28 and keeps an Overweight rating on the shares. The firm upped 2027 estimates to reflect the Centers for Medicare and Medicaid Services Austedo announcement.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Insider Selling Frenzy: AppLovin, Teva, AST SpaceMobile, MongoDB, and Western Digital Stocks in Focus!
- Teva Pharmaceutical Extends Revolving Facility Agreement
- FTC investigation prompts Teva request for removal of patents from Orange Book
- Teva price target raised to $32 from $29 at BofA
- Teva submits NDA to U.S. FDA for olanzapine